December 16, 2024 4 min read Large retrospective studies have demonstrated that visual impairment is a risk factor for developing cognitive impairment, including dementia.Cataracts, age-related macular degeneration and diabetic eye disease are directly correlated to dementia, but visual impairment from other causes can exacerbate the disease. Poor acuity in dementia … [Read more...] about Treating visual impairment to improve dementia status
News
EMA CHMP issues positive opinion for aflibercept biosimilar from Celltrion
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) announced opinions for three biosimilar candidates from Celltrion, including a biosimilar for reference product aflibercept (Eylea). The EMA issued a positive opinion and recommendation for marketing authorization for Eydenzelt (biosimilar aflibercept).According to a press release, … [Read more...] about EMA CHMP issues positive opinion for aflibercept biosimilar from Celltrion
All endpoints achieved in phase 3 trial of chronic thyroid eye disease treatment
December 16, 2024 1 min read Key takeaways: Veligrotug for chronic thyroid eye disease yielded improvements in proptosis, clinical activity scores and diplopia. Viridian plans to submit a biologics license application for veligrotug in 2025. A phase 3 clinical trial of veligrotug, an anti-insulin-like growth factor-1 receptor antibody, met primary and secondary … [Read more...] about All endpoints achieved in phase 3 trial of chronic thyroid eye disease treatment
Vabysmo prefilled syringe receives European approval
December 16, 2024 1 min read The European Medicines Agency approved the Vabysmo 6 mg prefilled syringe for three retinal conditions, according to a press release from Roche. The agency approved the single-dose Vabysmo (faricimab) prefilled syringe for the treatment of wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein … [Read more...] about Vabysmo prefilled syringe receives European approval
Atsena Therapeutics completes dosing in Part A of Phase I/II clinical trial evaluating ATSN-201 to treat X-linked retinoschisis
Atsena Therapeutics has announced dosing has been completed in Part A of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).According to the company, ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of … [Read more...] about Atsena Therapeutics completes dosing in Part A of Phase I/II clinical trial evaluating ATSN-201 to treat X-linked retinoschisis
Mark Humayun, MD, PhD, discusses advance stem cell-derived therapies for dry AMD
The California Institute for Regenerative Medicine (CIRM) has awarded a 2-year, $6 million grant to a team at the USC Dr. Allen and Charlotte Ginsburg Institute for Biomedical Therapeutics and the USC Roski Eye Institute advancing a new treatment for dry age-related macular degeneration, one of the leading causes of blindness in older adults.The funding will enable the … [Read more...] about Mark Humayun, MD, PhD, discusses advance stem cell-derived therapies for dry AMD
ACELYRIN announces phase 2b/3 trial of izokibep did not meet primary endpoint, ceases further additional internal investment
The phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint of a statistically significant improvement in time to treatment failure versus placebo as measured by treatment failure rates at 24 weeks. Based on these data, and previously announced guidance regarding other indications, ACELYRIN will not make any additional internal … [Read more...] about ACELYRIN announces phase 2b/3 trial of izokibep did not meet primary endpoint, ceases further additional internal investment
VIDEO: Emphasize better patient vision when redesigning ophthalmic practice website
December 14, 2024 4 min watch In this Healio Video Perspective, Cynthia Matossian, MD, FACS, and David Evans, PhD, MBA, discuss keys to effectively redesign a practice website. Evans advised ophthalmologists to focus the website on what really matters to patients: better vision. “The No. 1 message that your website has to communicate is solving their ‘see young, be … [Read more...] about VIDEO: Emphasize better patient vision when redesigning ophthalmic practice website
Researchers awarded $2.7 million NIH grant to study retinal connections in RP
A collaborative team from the University of Southern California (USC) and the University of Utah has secured a $2.7 million grant from the National Institutes of Health (NIH) to investigate how retinitis pigmentosa (RP), an incurable eye disease, disrupts the visual wiring in the retina. The study aims to uncover insights that could lead to strategies for slowing or preventing … [Read more...] about Researchers awarded $2.7 million NIH grant to study retinal connections in RP
Study links lower socioeconomic status to increased risk of open globe injury and poorer outcomes
A team of researchers has investigated the relationship between socioeconomic status (SES), as assessed by the Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry Social Vulnerability Index (SVI) and the Distressed Communities Index (DCI), and the characteristics of open globe injury (OGI).Prognosis is primarily determined by injury … [Read more...] about Study links lower socioeconomic status to increased risk of open globe injury and poorer outcomes